Gossamer Bio (GOSS) News Today → How to Make 100X on the AI Boom (From InvestorPlace) (Ad) Free GOSS Stock Alerts $0.73 +0.01 (+1.97%) (As of 03:46 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 5:41 AM | americanbankingnews.comFY2028 Earnings Forecast for Gossamer Bio, Inc. Issued By HC Wainwright (NASDAQ:GOSS)May 13 at 4:50 AM | americanbankingnews.comWedbush Weighs in on Gossamer Bio, Inc.'s Q1 2025 Earnings (NASDAQ:GOSS)May 11 at 4:11 AM | americanbankingnews.comQ3 2024 EPS Estimates for Gossamer Bio, Inc. Lifted by Leerink Partnrs (NASDAQ:GOSS)May 10, 2024 | businesswire.comGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Gossamer Bio Amidst Strategic Collaboration and Market Opportunity GrowthMay 10, 2024 | marketbeat.comBrokers Offer Predictions for Gossamer Bio, Inc.'s Q3 2024 Earnings (NASDAQ:GOSS)Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Equities researchers at Leerink Partnrs raised their Q3 2024 EPS estimates for Gossamer Bio in a research note issued on Wednesday, May 8th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($0.23) per shareMay 10, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Gossamer Bio, Inc. Lifted by Analyst (NASDAQ:GOSS)May 9, 2024 | bizjournals.comCary headquarters plays crucial role in $160 million dealMay 9, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Gossamer Bio, Inc. (NASDAQ:GOSS) Lowered by AnalystMay 9, 2024 | marketbeat.comWedbush Comments on Gossamer Bio, Inc.'s Q2 2024 Earnings (NASDAQ:GOSS)Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Wedbush lifted their Q2 2024 EPS estimates for Gossamer Bio in a research report issued on Monday, May 6th. Wedbush analyst L. Chico now anticipates that the company will earn $0.51 per share for the quarter, up from their previous estimate of ($0.May 8, 2024 | marketbeat.comGossamer Bio's (GOSS) Outperform Rating Reiterated at WedbushWedbush restated an "outperform" rating and issued a $4.00 price target on shares of Gossamer Bio in a research note on Wednesday.May 8, 2024 | msn.comGossamer Bio and Chiesi partner for pulmonary hypertension treatmentMay 8, 2024 | americanbankingnews.comGossamer Bio (NASDAQ:GOSS) Stock Rating Reaffirmed by HC WainwrightMay 7, 2024 | businesswire.comGossamer Bio Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 7, 2024 | markets.businessinsider.comBuy Rating on Gossamer Bio Supported by Strategic Partnership and Market UnderestimationMay 6, 2024 | finance.yahoo.comUPDATE 1-Gossamer Bio and Chiesi Group to collaborate in therapy for lung conditionMay 6, 2024 | finance.yahoo.comGossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions WorldwideMay 6, 2024 | marketbeat.comGossamer Bio's (GOSS) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Gossamer Bio in a research note on Monday.May 6, 2024 | reuters.comGossamer Bio and Chiesi Group to collaborate for blood pressure treatmentMay 6, 2024 | marketbeat.comTrading was temporarily halted for "GOSS" at 07:05 AM with a stated reason of "News pending."May 3, 2024 | businesswire.comGossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory MedicineMay 2, 2024 | msn.comWhat Ralph Waldo Emerson Knew About MoneyApril 26, 2024 | finance.yahoo.comGossamer Bio Decline Means Insider Profits Down To US$17kApril 5, 2024 | marketbeat.comGossamer Bio (NASDAQ:GOSS) Earns Outperform Rating from WedbushWedbush reissued an "outperform" rating and issued a $4.00 price objective on shares of Gossamer Bio in a research note on Friday.March 29, 2024 | insidertrades.comGossamer Bio, Inc. (NASDAQ:GOSS) CEO Faheem Hasnain Sells 23,172 SharesMarch 28, 2024 | marketbeat.comInsider Selling: Gossamer Bio, Inc. (NASDAQ:GOSS) CEO Sells 23,172 Shares of StockGossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) CEO Faheem Hasnain sold 23,172 shares of the business's stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $1.16, for a total value of $26,879.52. Following the completion of the transaction, the chief executive officer now owns 120,293 shares of the company's stock, valued at $139,539.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.March 27, 2024 | markets.businessinsider.comBuy Rating Affirmed on Gossamer Bio with Promising Seralutinib Prospects in PAH Treatment LandscapeMarch 27, 2024 | marketbeat.comGossamer Bio (NASDAQ:GOSS) Receives "Overweight" Rating from Piper SandlerPiper Sandler restated an "overweight" rating and issued a $15.00 price objective on shares of Gossamer Bio in a research note on Wednesday.March 21, 2024 | investing.comGossamer Bio EVP sells over $5,000 in company stockMarch 21, 2024 | investing.comGossamer Bio executive sells over $5,000 in company stockMarch 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Gossamer Bio (GOSS) and Vor Biopharma (VOR)March 18, 2024 | marketbeat.comGossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Down 6.5% in FebruaryGossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) was the recipient of a large decrease in short interest in February. As of February 29th, there was short interest totalling 14,300,000 shares, a decrease of 6.5% from the February 14th total of 15,300,000 shares. Based on an average daily trading volume, of 1,280,000 shares, the days-to-cover ratio is currently 11.2 days.March 16, 2024 | ca.finance.yahoo.comGOSS Apr 2024 1.500 putMarch 16, 2024 | finance.yahoo.comGOSS Apr 2024 1.000 putMarch 13, 2024 | theguardian.comTara Rae Moss: ‘So many doctors in different continents told me that I would never recover’March 12, 2024 | finance.yahoo.comGossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of DirectorsMarch 12, 2024 | businesswire.comGossamer Bio Announces Appointment of Steven D. Nathan, M.D.March 11, 2024 | markets.businessinsider.comBarclays Keeps Their Hold Rating on Gossamer Bio (GOSS)March 8, 2024 | marketbeat.comGossamer Bio, Inc. (NASDAQ:GOSS) to Post FY2026 Earnings of ($0.72) Per Share, Wedbush ForecastsGossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Investment analysts at Wedbush reduced their FY2026 earnings estimates for Gossamer Bio in a research report issued to clients and investors on Tuesday, March 5th. Wedbush analyst A. Argyrides now forecasts that the company will earn ($0.72) per shMarch 7, 2024 | markets.businessinsider.comOptimistic Buy Rating for Gossamer Bio Amidst Progress in PAH Treatment MarketMarch 7, 2024 | marketbeat.comHC Wainwright Research Analysts Lower Earnings Estimates for Gossamer Bio, Inc. (NASDAQ:GOSS)Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - HC Wainwright reduced their FY2028 earnings estimates for shares of Gossamer Bio in a research report issued to clients and investors on Wednesday, March 6th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $0.30 per sharMarch 6, 2024 | markets.businessinsider.comGossamer Bio Earns ‘Buy’ Rating from Analyst Citing Progress in Seralutinib Trials and Strategic Market ExpansionMarch 6, 2024 | marketbeat.comGossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Rating of "Hold" from AnalystsShares of Gossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) have been given a consensus recommendation of "Hold" by the five analysts that are currently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and two have issued a buy rating on the cMarch 6, 2024 | marketbeat.comGossamer Bio (NASDAQ:GOSS) Given "Outperform" Rating at WedbushWedbush reaffirmed an "outperform" rating and set a $6.00 price target on shares of Gossamer Bio in a research note on Wednesday.March 6, 2024 | marketbeat.comGossamer Bio (NASDAQ:GOSS) Price Target Lowered to $8.00 at The Goldman Sachs GroupThe Goldman Sachs Group lowered their target price on Gossamer Bio from $9.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday.March 5, 2024 | investorplace.comGOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023March 5, 2024 | marketbeat.comGossamer Bio (NASDAQ:GOSS) Announces Earnings ResultsGossamer Bio (NASDAQ:GOSS - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.21) EPS for the quarter, hitting analysts' consensus estimates of ($0.21).March 5, 2024 | markets.businessinsider.comGossamer Bio Posts Narrower Loss In Q4 - Quick FactsMarch 5, 2024 | businesswire.comGossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateMarch 3, 2024 | marketbeat.comArmistice Capital LLC Invests $4.13 Million in Gossamer Bio, Inc. (NASDAQ:GOSS)Armistice Capital LLC bought a new position in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,956,000 shares of the company's stock, valued at approx Get Gossamer Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden to Drop BOMBSHELL June 13th? (Ad)Biden’s days are numbered! According to a former CIA and Pentagon insider… He’s about to drop out of the presidential race on June 13th! Click here now to see his shocking evidence. GOSS Media Mentions By Week GOSS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GOSS News Sentiment▼0.380.57▲Average Medical News Sentiment GOSS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GOSS Articles This Week▼322▲GOSS Articles Average Week Get Gossamer Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MCRB News Today PRQR News Today CAPR News Today SKYE News Today PRLD News Today GLSI News Today SCPH News Today IXHL News Today CRVO News Today IVA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GOSS) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldThis 1 Biotech Stock has been shocking the marketsHuge AlertsHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportElon’s New Device is About to Shock the WorldInvestorPlaceAmerica’s worst nightmare?Porter & CompanyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
